Phase I studies of CBP501, a novel G2 checkpoint abrogator, alone and combined with cisplatin (CDDP) in advanced solid tumor patients (pts) No significant financial relationships to disclose. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results